Farmakokinetika i apsorpcija farmaceutsko-tehnološke formulacije gliklazida u obliku mikrovezikula

  • Jelena Jović University of Novi Sad, Faculty of Medicine, Department of Pharmacology and Toxicology, Novi Sad
  • Boris Milijašević University of Novi Sad, Faculty of Medicine, Department of Pharmacology and Toxicology, Novi Sad, Serbia
  • Saša Vukmirović University of Novi Sad, Faculty of Medicine, Department of Pharmacology and Toxicology, Novi Sad, Serbia
  • Velibor Vasović University of Novi Sad, Faculty of Medicine, Department of Pharmacology and Toxicology, Novi Sad, Serbia
  • Momir Mikov University of Novi Sad, Faculty of Medicine, Department of Pharmacology and Toxicology, Novi Sad, Serbia
  • Armin Mooranian Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Australia
  • Hani Al-Salami Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Australia
  • Svetlana Goločorbin-Kon University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, Serbia
DOI: https://doi.org/10.5937/scriptamed51-25521

Sažetak


Background: Gliclazide is one of the most commonly prescribed oral anti-hyperglycemic therapies in Type 2 diabetes mellitus (T2D). Recently reported additional beneficial pharmacological properties of gliclazide, including immunomodulatory and anticoagulant activities, suggested its potential application in treatment of Type 1 diabetes mellitus (T1D). However, following oral administration, gliclazide was shown to have poor and variable absorption directing research into development of novel pharmaceutical delivery systems of gliclazide suitable for T1D. Since bile acids have previously demonstrated stabilizing and controlled-release effects on microcapsules, their use for preparation of microcapsules of gliclazide may lead to improvements in gliclazide release, absorption and antidiabetic effects. Aim: To evaluate drug absorption profiles and hypoglycemic effects of alginate-based microcapsules of gliclazide, prepared together with or without cholic acid, in healthy rats. Methods: Thirty healthy Wistar rats with confirmed normal glucose concentration of in the blood were allocated into five groups and administered with a single dose of either vehicle microcapsules, gliclazide in suspension, gliclazide microcapsules, gliclazide in suspension together with cholic acid or microencapsulated gliclazide in combination with cholic acid. Following respective gliclazide dose, blood was sampled over next 10 hours and blood glucose levels and gliclazide serum concentrations were measured. Results: Our analysis demonstrated altered effects of different gliclazide formulations in healthy rats with the highest gliclazide absorption mirrored by the most profound hypoglycemic effect being achieved after its oral administration as a suspension (p<0.01) compared to any other investigated pharmaceutical formulation. Conclusion: When conducting pharmacokinetic characterization of novel pharmaceutical formulations of antidiabetic drugs, it is of utmost importance to select the appropriate research model and consider the possible role of gut-metabolic activation on their hypoglycemic effects.

Reference

1. Genuth S. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it’s time to move on!. Diabetes Care. 2015; 1;38(1):170-5.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/25538314
2. Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metab Clin Exp. 2000;49(10 Suppl 2):17–20.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/11078471
3. Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T, et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism. 2010;59(9):1294-9.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/20070990
4. Desfaits AC, Serri O, Renier G. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. Metab Clin Exp. 1997;46(10):1150–6.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/9322798
5. Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and Pharmaceutical Profile of Gliclazide: a Review. J Appl Pharm Sci. 2011;1(9):11–9.
Available from: https://www.japsonline.com/abstract.php?article_id=253
6. Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2012;37(2):99–108.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/21874525
7. Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes.. Eur J Drug Metab Pharmacokinet. 2008;33(3):137–42.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/19007038
8. Mikov M, Đanić M, Pavlović N, Stanimirov B, Goločorbin-Kon S, Stankov K, et al. Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics. Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):269-280.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/29039071
9. Davis TM, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ, et al. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol. 2000;49:223–230.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/10718777
10. McGavin JK, Perry CM, Goa KL. Gliclazide modified release. Drugs. 2002 Jun 1;62(9):1357-64.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/12076188
11. Al-Kassas RS, Al-Gohary OMN, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm. 2007;341(1–2):230–7.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/17507189
12. Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151–6.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/25265061
13. Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Devel Ther. 2014;8:1003–12.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/25114507
14. Mathavan S, Chen-Tan N, Arfuso F, Al-Salami H. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of type-1 diabetes. Drug Deliv. 2016;23(8):2869–80.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/26610261
15. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 2014; 9(2): 150–157.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013442/
16. Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharmaceutical Development and Technology. 2015;20(6):702-9.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/24798888
17. Golocorbin-Kon S, Calasan J, Milijasevic B, Vukmirovic S, Lalic-Popovic M, Mikov M, et al. High-loading dose of microencapsulated gliclazide formulation exerted a hypoglycaemic effect on type 1 diabetic rats and incorporation of a primary deconjugated bile acid, diminished the hypoglycaemic antidiabetic effect. Eur J Drug Metab Pharmacokinet. 2017; 42(6):1005-1011.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/28547295
18. Stepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos. 2002;30(8):861-8.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/12124302
19. Marathe PH, Wen Y, Norton J, Greene DS, Barbhaiya RH, Wilding IR. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. British journal of clinical pharmacology. 2000;50(4):325-32.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2015004/
20. Stětinová V, Květina J, Pastera J, Polásková A, Prazáková M. Gliclazide: pharmacokinetic–pharmacodynamic relationships in rats. Biopharm Drug Dispos. 2007 Jul;28(5):241-8.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/17415747
21. Resztak M, Hermann TW, Sawicki W, Danielak DZ. Pharmacokinetics and Pharmacodynamics of Gliclazide from Immediate and Modified Release Formulation Tablets in Rats. Iran J Pharm Res. 2014; 13(1): 29–37.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/24734054
Objavljeno
2020/03/27
Broj časopisa
Vol. 51 Br. 1 (2020)
Rubrika
Originalni naučni članak
Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).